<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/5bd3404007bffd2a.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/391-7f9e7fb294aae160.js" async=""></script><script src="/_next/static/chunks/app/layout-6784eb5ba9ddff8d.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>DXB share price, analysis &amp; company profile - Dimerix Limited | ASX Desk</title><meta name="description" content="Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/DXB/"/><meta property="og:title" content="DXB share price, analysis &amp; company profile - Dimerix Limited"/><meta property="og:description" content="Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/DXB/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="DXB share price, analysis &amp; company profile - Dimerix Limited"/><meta name="twitter:description" content="Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/ipos/">IPOs</a><a class="transition hover:text-white" href="/compare/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does DXB do?","acceptedAnswer":{"@type":"Answer","text":"Dimerix Limited is an Australian biotech company developing novel drug therapies for kidney and inflammatory diseases. Its primary focus is on advancing its lead product candidate, DMX-200, which is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney condition."}},{"@type":"Question","name":"Is DXB a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in DXB is considered highly speculative, characteristic of clinical-stage biotechnology companies. While there is significant upside potential if its lead candidate, DMX-200, successfully completes trials and gains regulatory approval, there is also a high risk of capital loss if clinical development fails, regulatory hurdles are insurmountable, or market adoption is limited. It's suitable for investors with a high-risk tolerance."}},{"@type":"Question","name":"What drives DXB's share price?","acceptedAnswer":{"@type":"Answer","text":"DXB's share price is primarily driven by progress and outcomes of its clinical trials, particularly the Phase 3 CLARITY study for DMX-200. Key catalysts include trial data readouts, regulatory approvals or designations, and announcements of commercialisation partnerships or capital raising activities. News regarding competitor drugs or broader biotech sector sentiment can also play a role."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Dimerix Limited<!-- --> (<!-- -->DXB<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Dimerix Limited is an Australian clinical-stage biotechnology company focused on developing innovative new therapies for kidney and inflammatory diseases. Its lead candidate, DMX-200, is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder. The company&#x27;s pipeline leverages its proprietary G protein-coupled receptor (GPCR) technology.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$318M</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold mb-4">Price Chart</h2><div id="tradingview-widget-DXB" style="height:700px;width:100%"><div class="flex h-full items-center justify-center"><div class="flex items-center gap-3 text-sm text-slate-400"><svg class="h-5 w-5 animate-spin text-blue-400" viewBox="0 0 24 24" fill="none"><circle cx="12" cy="12" r="10" stroke="currentColor" stroke-width="3" class="opacity-25"></circle><path d="M4 12a8 8 0 018-8" stroke="currentColor" stroke-width="3" stroke-linecap="round" class="opacity-75"></path></svg>Loading chartâ€¦</div></div></div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>Currently, Dimerix operates as a pre-revenue biotechnology company, with its primary value derived from its robust pipeline of drug candidates and intellectual property. The company&#x27;s lead asset, DMX-200, is undergoing a global Phase 3 CLARITY study for FSGS, an orphan disease, which represents a significant market opportunity if successful. Recent performance has been tied to trial enrolment progress and regulatory milestones.</p><p>The growth outlook for Dimerix is highly contingent on the successful progression of its clinical trials and regulatory approvals for DMX-200. Key catalysts in the near to medium term include the readout of the CLARITY study results, potential regulatory submissions (e.g., FDA, EMA), and securing a commercialisation partner for DMX-200, particularly in major pharmaceutical markets. The strategic direction is focused on bringing DMX-200 through to approval and exploring its potential in other kidney or inflammatory indications.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Positive top-line results from the global Phase 3 CLARITY study for DMX-200 in FSGS, demonstrating significant efficacy and safety.</li><li>â€¢ <!-- -->Securing regulatory approval (e.g., FDA, EMA, TGA) for DMX-200 in FSGS, leading to market access and commercialisation potential.</li><li>â€¢ <!-- -->Execution of a significant licensing or partnership agreement with a large pharmaceutical company for global commercialisation of DMX-200.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Unfavourable or inconclusive results from the Phase 3 CLARITY study, leading to delays or discontinuation of the development program for DMX-200.</li><li>â€¢ <!-- -->Failure to secure regulatory approval for DMX-200 due to safety concerns, lack of sufficient efficacy, or other regulatory hurdles.</li><li>â€¢ <!-- -->Further capital raises required to fund ongoing operations and clinical trials, leading to significant shareholder dilution at current market valuations.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Market Sentiment</h3><div class="mt-4 flex items-center gap-3"><span class="inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400">ðŸŸ¡<!-- --> <!-- -->Mixed</span><span class="text-xs text-slate-500">Score: <!-- -->+<!-- -->0.04</span></div><div class="mt-4"><div class="flex justify-between text-[10px] uppercase tracking-widest text-slate-500"><span>Bearish</span><span>Bullish</span></div><div class="relative mt-1 h-2 rounded-full bg-ink-900/60"><div class="absolute left-1/2 top-0 h-full w-px bg-slate-600"></div><div class="absolute top-0 h-full w-2 rounded-full bg-yellow-500" style="left:calc(52% - 4px)"></div></div></div><div class="mt-4 flex gap-4 text-xs"><span class="text-emerald-400">â–² <!-- -->2<!-- --> bullish</span><span class="text-red-400">â–¼ <!-- -->0<!-- --> bearish</span><span class="text-slate-500">51<!-- --> neutral</span></div><p class="mt-1 text-xs text-slate-500">Based on <!-- -->53<!-- --> social post<!-- -->s</p><div class="mt-4 space-y-2"><p class="text-xs uppercase tracking-widest text-slate-500">Recent mentions</p><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-05</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Neutral introduction to Dimerix</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-06</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Introduction to Dimerix Limited</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-06</span><span class="text-slate-400">â€”</span></div><p class="mt-1.5 text-slate-300">Introduction to Dimerix Limited</p></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Dimerix to Present at Euroz Hartleys Healthcare Forum 2026</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>4 Feb 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">General</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly Appendix 4C and Activities Report</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>28 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div><p class="mt-2 text-xs text-slate-400">DXB, a commitments test entity on ASX, has released its quarterly report detailing financial activities for the period. Investors should review this document to assess DXB&#x27;s compliance with regulatory requirements and current financial health.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Appointment of CFO/Company Secretary</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>20 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">General</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does DXB do?</p><p class="text-slate-400">Dimerix Limited is an Australian biotech company developing novel drug therapies for kidney and inflammatory diseases. Its primary focus is on advancing its lead product candidate, DMX-200, which is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney condition.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is DXB a good investment?</p><p class="text-slate-400">Investing in DXB is considered highly speculative, characteristic of clinical-stage biotechnology companies. While there is significant upside potential if its lead candidate, DMX-200, successfully completes trials and gains regulatory approval, there is also a high risk of capital loss if clinical development fails, regulatory hurdles are insurmountable, or market adoption is limited. It&#x27;s suitable for investors with a high-risk tolerance.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives DXB&#x27;s share price?</p><p class="text-slate-400">DXB&#x27;s share price is primarily driven by progress and outcomes of its clinical trials, particularly the Phase 3 CLARITY study for DMX-200. Key catalysts include trial data readouts, regulatory approvals or designations, and announcements of commercialisation partnerships or capital raising activities. News regarding competitor drugs or broader biotech sector sentiment can also play a role.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->0.53</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-emerald-400">26.5<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$318M</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">04/02/1993</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->163.44</p><p class="text-xs font-semibold text-red-400">-34.4<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company&#x27;s core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$83.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->1.00</p><p class="text-xs font-semibold text-red-400">-12.7<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$694M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.00</p><p class="text-xs font-semibold text-red-400">-40.5<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/5bd3404007bffd2a.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[2885,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"default\"]\n8:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"\"]\n9:I[9275,[],\"\"]\nb:I[1343,[],\"\"]\nc:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-7f9e7fb294aae160.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"Image\"]\nd:I[4019,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"391\",\"static/chunks/391-7f9e7fb294aae160.js\",\"185\",\"static/chunks/app/layout-6784eb5ba9ddff8d.js\"],\"default\"]\nf:I[6130,[],\"\"]\n6:T5fc,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does DXB do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dimerix Limited is an Australian biotech company developing novel drug therapies for kidney and inflammatory diseases. Its primary focus is on advancing its lead product candidate, DMX-200, which is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney condition.\"}},{\"@type\":\"Question\",\"name\":\"Is DXB a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investing in DXB is considered highly speculative, characteristic of clinical-stage biotechnology companies. While there is significant upside potential if its lead candidate, DMX-200, successfully completes trials and gains regulatory approval, there is also a high risk of capital loss if clinical development fails, regulatory hurdles are insurmountable, or market adoption is limited. It's suitable for investors with a high-risk tolerance.\"}},{\"@type\":\"Question\",\"name\":\"What drives DXB's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"DXB's share price is primarily driven by progress and outcomes of its clinical trials, particularly the Phase 3 CLARITY study for DMX-200. Key catalysts i"])</script><script>self.__next_f.push([1,"nclude trial data readouts, regulatory approvals or designations, and announcements of commercialisation partnerships or capital raising activities. News regarding competitor drugs or broader biotech sector sentiment can also play a role.\"}}]}a:[\"ticker\",\"DXB\",\"d\"]\n10:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/5bd3404007bffd2a.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"ujAyz4UDjjKKgpu0I6XQ2\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/DXB/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"DXB\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"DXB\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"DXB\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Dimerix Limited\",\" (\",\"DXB\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Dimerix Limited is an Australian clinical-stage biotechnology company focused on developing innovative new therapies for kidney and inflammatory diseases. Its lead candidate, DMX-200, is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder. The company's pipeline leverages its proprietary G protein-coupled receptor (GPCR) technology.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$318M\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"$L7\",null,{\"ticker\":\"DXB\"}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"Currently, Dimerix operates as a pre-revenue biotechnology company, with its primary value derived from its robust pipeline of drug candidates and intellectual property. The company's lead asset, DMX-200, is undergoing a global Phase 3 CLARITY study for FSGS, an orphan disease, which represents a significant market opportunity if successful. Recent performance has been tied to trial enrolment progress and regulatory milestones.\",{\"children\":\"Currently, Dimerix operates as a pre-revenue biotechnology company, with its primary value derived from its robust pipeline of drug candidates and intellectual property. The company's lead asset, DMX-200, is undergoing a global Phase 3 CLARITY study for FSGS, an orphan disease, which represents a significant market opportunity if successful. Recent performance has been tied to trial enrolment progress and regulatory milestones.\"}],[\"$\",\"p\",\"The growth outlook for Dimerix is highly contingent on the successful progression of its clinical trials and regulatory approvals for DMX-200. Key catalysts in the near to medium term include the readout of the CLARITY study results, potential regulatory submissions (e.g., FDA, EMA), and securing a commercialisation partner for DMX-200, particularly in major pharmaceutical markets. The strategic direction is focused on bringing DMX-200 through to approval and exploring its potential in other kidney or inflammatory indications.\",{\"children\":\"The growth outlook for Dimerix is highly contingent on the successful progression of its clinical trials and regulatory approvals for DMX-200. Key catalysts in the near to medium term include the readout of the CLARITY study results, potential regulatory submissions (e.g., FDA, EMA), and securing a commercialisation partner for DMX-200, particularly in major pharmaceutical markets. The strategic direction is focused on bringing DMX-200 through to approval and exploring its potential in other kidney or inflammatory indications.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Positive top-line results from the global Phase 3 CLARITY study for DMX-200 in FSGS, demonstrating significant efficacy and safety.\",{\"children\":[\"â€¢ \",\"Positive top-line results from the global Phase 3 CLARITY study for DMX-200 in FSGS, demonstrating significant efficacy and safety.\"]}],[\"$\",\"li\",\"Securing regulatory approval (e.g., FDA, EMA, TGA) for DMX-200 in FSGS, leading to market access and commercialisation potential.\",{\"children\":[\"â€¢ \",\"Securing regulatory approval (e.g., FDA, EMA, TGA) for DMX-200 in FSGS, leading to market access and commercialisation potential.\"]}],[\"$\",\"li\",\"Execution of a significant licensing or partnership agreement with a large pharmaceutical company for global commercialisation of DMX-200.\",{\"children\":[\"â€¢ \",\"Execution of a significant licensing or partnership agreement with a large pharmaceutical company for global commercialisation of DMX-200.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Unfavourable or inconclusive results from the Phase 3 CLARITY study, leading to delays or discontinuation of the development program for DMX-200.\",{\"children\":[\"â€¢ \",\"Unfavourable or inconclusive results from the Phase 3 CLARITY study, leading to delays or discontinuation of the development program for DMX-200.\"]}],[\"$\",\"li\",\"Failure to secure regulatory approval for DMX-200 due to safety concerns, lack of sufficient efficacy, or other regulatory hurdles.\",{\"children\":[\"â€¢ \",\"Failure to secure regulatory approval for DMX-200 due to safety concerns, lack of sufficient efficacy, or other regulatory hurdles.\"]}],[\"$\",\"li\",\"Further capital raises required to fund ongoing operations and clinical trials, leading to significant shareholder dilution at current market valuations.\",{\"children\":[\"â€¢ \",\"Further capital raises required to fund ongoing operations and clinical trials, leading to significant shareholder dilution at current market valuations.\"]}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Market Sentiment\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center gap-3\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400\",\"children\":[\"ðŸŸ¡\",\" \",\"Mixed\"]}],[\"$\",\"span\",null,{\"className\":\"text-xs text-slate-500\",\"children\":[\"Score: \",\"+\",\"0.04\"]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between text-[10px] uppercase tracking-widest text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"Bearish\"}],[\"$\",\"span\",null,{\"children\":\"Bullish\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative mt-1 h-2 rounded-full bg-ink-900/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute left-1/2 top-0 h-full w-px bg-slate-600\"}],[\"$\",\"div\",null,{\"className\":\"absolute top-0 h-full w-2 rounded-full bg-yellow-500\",\"style\":{\"left\":\"calc(52% - 4px)\"}}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-4 text-xs\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":[\"â–² \",2,\" bullish\"]}],[\"$\",\"span\",null,{\"className\":\"text-red-400\",\"children\":[\"â–¼ \",0,\" bearish\"]}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":[51,\" neutral\"]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1 text-xs text-slate-500\",\"children\":[\"Based on \",53,\" social post\",\"s\"]}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-widest text-slate-500\",\"children\":\"Recent mentions\"}],[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-05\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Neutral introduction to Dimerix\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-06\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Introduction to Dimerix Limited\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-06\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"â€”\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Introduction to Dimerix Limited\"}]]}]]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Dimerix to Present at Euroz Hartleys Healthcare Forum 2026\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"4 Feb 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"General\"}]]}],\"\"]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly Appendix 4C and Activities Report\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"28 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"DXB, a commitments test entity on ASX, has released its quarterly report detailing financial activities for the period. Investors should review this document to assess DXB's compliance with regulatory requirements and current financial health.\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Appointment of CFO/Company Secretary\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"20 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"General\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does DXB do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does DXB do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Dimerix Limited is an Australian biotech company developing novel drug therapies for kidney and inflammatory diseases. Its primary focus is on advancing its lead product candidate, DMX-200, which is currently in a global Phase 3 clinical trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney condition.\"}]]}],[\"$\",\"div\",\"Is DXB a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is DXB a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Investing in DXB is considered highly speculative, characteristic of clinical-stage biotechnology companies. While there is significant upside potential if its lead candidate, DMX-200, successfully completes trials and gains regulatory approval, there is also a high risk of capital loss if clinical development fails, regulatory hurdles are insurmountable, or market adoption is limited. It's suitable for investors with a high-risk tolerance.\"}]]}],[\"$\",\"div\",\"What drives DXB's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives DXB's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"DXB's share price is primarily driven by progress and outcomes of its clinical trials, particularly the Phase 3 CLARITY study for DMX-200. Key catalysts include trial data readouts, regulatory approvals or designations, and announcements of commercialisation partnerships or capital raising activities. News regarding competitor drugs or broader biotech sector sentiment can also play a role.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"0.53\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-emerald-400\",\"children\":[\"26.5\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$318M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"04/02/1993\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/asx/CSL\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"163.44\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-34.4\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company's core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$83.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/PNV\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"1.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-12.7\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$694M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/1AD\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.00\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-40.5\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$a\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lc\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L8\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L8\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L8\",\"/sectors\",{\"href\":\"/sectors\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L8\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L8\",\"/ipos\",{\"href\":\"/ipos\",\"className\":\"transition hover:text-white\",\"children\":\"IPOs\"}],[\"$\",\"$L8\",\"/compare\",{\"href\":\"/compare\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L8\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Ld\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Ld\",null,{}]}],[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Le\"],\"globalErrorComponent\":\"$f\",\"missingSlots\":\"$W10\"}]]\n"])</script><script>self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"DXB share price, analysis \u0026 company profile - Dimerix Limited | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/DXB/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"DXB share price, analysis \u0026 company profile - Dimerix Limited\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/DXB/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"DXB share price, analysis \u0026 company profile - Dimerix Limited\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest DXB share price overview, what Dimerix Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>